The site is undergoing maintenance on
Thursday, September 10, 7:00 pm through Friday, September 11, 3:00 am (CEST), 2026.
If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
See More
The site is undergoing maintenance on
Thursday, September 10, 7:00 pm through Friday, September 11, 3:00 am (CEST), 2026.
If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
See MoreThe site is undergoing maintenance on
Thursday, September 10, 7:00 pm through Friday, September 11, 3:00 am (CEST), 2026
.If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Two-color flow cytometric analysis of CXCR6 (CD186) expression on human peripheral blood cells. Human peripheral blood cells were freshly stained with APC Mouse Anti-Human CD3 antibody (Cat. No. 555342/561804) and either BD Horizon™ BV421 Anti-Human CXCR6 (CD186) (Cat. No. 566007/566008) or BD Horizon BV421 Mouse IgG2a, κ Isotype Control (Cat. No. 562439). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). The two-color contour plots showing the correlated expression of CXCR6 (CD186) [or Ig Isotype control staining] versus CD3 were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometric analysis was performed using a BD LSRFortessa™ X-20 Cell Analyzer System.
Flow cytometric analysis of CXCR6 (CD186) expression on IL-2-stimulated lymphocytes. Human PBMC were cultured (9 days) with Recombinant Human IL-2 (Cat. No. 554603). Cells were stained with BD Horizon Fixable Viability Stain 660 (FVS660; Cat. No. 564405) for exclusion of dead cells and then with either BD Horizon BV421 Mouse IgG2a, κ Isotype Control (dashed line histogram) or BD Horizon BV421 Anti-Human CXCR6 (CD186) antibody (solid line histogram). The histograms showing CXCR6 (CD186) expression (or Ig Isotype control staining) were derived from gated events with the forward and side light-scatter characteristics of viable FVS660-negative lymphocytes using a BD LSRFortessa™ X-20 Cell Analyzer System.
Two-color flow cytometric analysis of CXCR6 (CD186) expression on human peripheral blood cells. Human peripheral blood cells were freshly stained with APC Mouse Anti-Human CD3 antibody (Cat. No. 555342/561804) and either BD Horizon™ BV421 Anti-Human CXCR6 (CD186) (Cat. No. 566007/566008) or BD Horizon BV421 Mouse IgG2a, κ Isotype Control (Cat. No. 562439). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). The two-color contour plots showing the correlated expression of CXCR6 (CD186) [or Ig Isotype control staining] versus CD3 were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometric analysis was performed using a BD LSRFortessa™ X-20 Cell Analyzer System.
Flow cytometric analysis of CXCR6 (CD186) expression on IL-2-stimulated lymphocytes. Human PBMC were cultured (9 days) with Recombinant Human IL-2 (Cat. No. 554603). Cells were stained with BD Horizon Fixable Viability Stain 660 (FVS660; Cat. No. 564405) for exclusion of dead cells and then with either BD Horizon BV421 Mouse IgG2a, κ Isotype Control (dashed line histogram) or BD Horizon BV421 Anti-Human CXCR6 (CD186) antibody (solid line histogram). The histograms showing CXCR6 (CD186) expression (or Ig Isotype control staining) were derived from gated events with the forward and side light-scatter characteristics of viable FVS660-negative lymphocytes using a BD LSRFortessa™ X-20 Cell Analyzer System.
Two-color flow cytometric analysis of CXCR6 (CD186) expression on human peripheral blood cells. Human peripheral blood cells were freshly stained with APC Mouse Anti-Human CD3 antibody (Cat. No. 555342/561804) and either BD Horizon™ BV421 Anti-Human CXCR6 (CD186) (Cat. No. 566007/566008) or BD Horizon BV421 Mouse IgG2a, κ Isotype Control (Cat. No. 562439). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). The two-color contour plots showing the correlated expression of CXCR6 (CD186) [or Ig Isotype control staining] versus CD3 were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometric analysis was performed using a BD LSRFortessa™ X-20 Cell Analyzer System.
Flow cytometric analysis of CXCR6 (CD186) expression on IL-2-stimulated lymphocytes. Human PBMC were cultured (9 days) with Recombinant Human IL-2 (Cat. No. 554603). Cells were stained with BD Horizon Fixable Viability Stain 660 (FVS660; Cat. No. 564405) for exclusion of dead cells and then with either BD Horizon BV421 Mouse IgG2a, κ Isotype Control (dashed line histogram) or BD Horizon BV421 Anti-Human CXCR6 (CD186) antibody (solid line histogram). The histograms showing CXCR6 (CD186) expression (or Ig Isotype control staining) were derived from gated events with the forward and side light-scatter characteristics of viable FVS660-negative lymphocytes using a BD LSRFortessa™ X-20 Cell Analyzer System.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).
The 13B 1E5 monoclonal antibody specifically binds to C-X-C chemokine receptor type 6 (CXCR6), which is also known as CD186, BONZO, T-lymphocyte-expressed seven-transmembrane domain receptor (TYMSTR), and Seven transmembrane receptor-like from clone 33 (STRL33). CXCR6 is a G-protein coupled chemokine receptor that is expressed on subsets of activated and memory T cells and NKT cells. CXCR6 binds to soluble CXCL16 and membrane-anchored CXCL16 expressed by dendritic cells and macrophages. The CXCL16 and CXCR6 interaction activates Akt and mTor signaling. This regulates cellular migration including the recruitment of tumor-infiltrating lymphocytes and may contribute to the progression and metastasis of various cancers. CXCR6 also can serve as a coreceptor for certain strains of HIV-1 and HIV-2.
The antibody was conjugated to BD Horizon BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max at 421-nm, BD Horizon BV421 can be excited by the violet laser and detected in the standard Pacific Blue™ filter set (eg, 450/50-nm filter). BD Horizon BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue conjugates.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.